NL177493C - Werkwijze voor de bereiding van steroiden en werkwijze ter bereiding van een farmaceutisch preparaat tegen ontstekingen. - Google Patents

Werkwijze voor de bereiding van steroiden en werkwijze ter bereiding van een farmaceutisch preparaat tegen ontstekingen.

Info

Publication number
NL177493C
NL177493C NLAANVRAGE7306978,A NL7306978A NL177493C NL 177493 C NL177493 C NL 177493C NL 7306978 A NL7306978 A NL 7306978A NL 177493 C NL177493 C NL 177493C
Authority
NL
Netherlands
Prior art keywords
preparation
steroids
against inflammation
pharmaceutical
pharmaceutical preparation
Prior art date
Application number
NLAANVRAGE7306978,A
Other languages
English (en)
Dutch (nl)
Other versions
NL177493B (nl
NL7306978A (de
Original Assignee
Draco Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20269234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL177493(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Draco Ab filed Critical Draco Ab
Publication of NL7306978A publication Critical patent/NL7306978A/xx
Publication of NL177493B publication Critical patent/NL177493B/xx
Application granted granted Critical
Publication of NL177493C publication Critical patent/NL177493C/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/0026Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NLAANVRAGE7306978,A 1972-05-19 1973-05-18 Werkwijze voor de bereiding van steroiden en werkwijze ter bereiding van een farmaceutisch preparaat tegen ontstekingen. NL177493C (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206644A SE378109B (de) 1972-05-19 1972-05-19

Publications (3)

Publication Number Publication Date
NL7306978A NL7306978A (de) 1973-11-21
NL177493B NL177493B (nl) 1985-05-01
NL177493C true NL177493C (nl) 1985-10-01

Family

ID=20269234

Family Applications (2)

Application Number Title Priority Date Filing Date
NLAANVRAGE7306978,A NL177493C (nl) 1972-05-19 1973-05-18 Werkwijze voor de bereiding van steroiden en werkwijze ter bereiding van een farmaceutisch preparaat tegen ontstekingen.
NL930025C NL930025I1 (nl) 1972-05-19 1993-04-13 Werkwijze voor de bereiding van steroïden en werkwijze ter bereiding van een farmaceutisch preparaattegen ontstekingen

Family Applications After (1)

Application Number Title Priority Date Filing Date
NL930025C NL930025I1 (nl) 1972-05-19 1993-04-13 Werkwijze voor de bereiding van steroïden en werkwijze ter bereiding van een farmaceutisch preparaattegen ontstekingen

Country Status (26)

Country Link
US (2) US3929768A (de)
JP (1) JPS5521760B2 (de)
AT (1) AT328630B (de)
BE (1) BE799727A (de)
CA (1) CA1002938A (de)
CH (1) CH595400A5 (de)
CS (1) CS178129B2 (de)
CY (1) CY1013A (de)
DD (1) DD104295A5 (de)
DE (1) DE2323215C3 (de)
DK (1) DK134783B (de)
ES (1) ES414673A1 (de)
FI (1) FI50631C (de)
FR (1) FR2185405B1 (de)
GB (1) GB1429922A (de)
HK (1) HK49179A (de)
HU (1) HU166680B (de)
IL (1) IL42155A (de)
KE (1) KE2970A (de)
NL (2) NL177493C (de)
NO (2) NO139640C (de)
PL (1) PL87765B1 (de)
SE (1) SE378109B (de)
SU (1) SU470954A3 (de)
YU (1) YU35896B (de)
ZA (1) ZA732955B (de)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004580L (sv) * 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8403905D0 (sv) * 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
SE8501693D0 (sv) * 1985-04-04 1985-04-04 Draco Ab Novel 16,17-acetalsubstituted androstane-17beta-carboxylic acid esters
SE8506015D0 (sv) * 1985-12-19 1985-12-19 Draco Ab Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
US5215979A (en) * 1985-12-19 1993-06-01 Aktiebolaget Draco 16,17-acetalsubstituted pregnane 21-oic acid derivatives
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
LV5274A3 (lv) * 1988-02-29 1993-10-10 Richter Gedeon Vegyeszet 22(R,S)-11 beta,21-dihidroksi-16 alpha,17-butilidenbisoksipregna-1,4-dien-3,20-diona iegusanas panemiens
HU203769B (en) * 1989-03-09 1991-09-30 Richter Gedeon Vegyeszet Process for producing new steroide derivatives and pharmaceutical compositions containing them
SE8903219D0 (sv) * 1989-10-02 1989-10-02 Astra Ab Process for the manufacture of budesonide
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
FR2675146A1 (fr) * 1991-04-10 1992-10-16 Roussel Uclaf Nouveaux derives sterouides de la pregna-1,4-diene-3,20-dione, leur preparation, leur application a la preparation de derives 16,17-methylene dioxy substitues et nouveaux intermediaires.
MD24C2 (ro) * 1991-07-09 1994-05-31 Fabrica De Parfumerii Si Cosmetica "Viorica" Compoziţie de substanţe odorante
LT3695B (en) 1991-11-18 1996-02-26 Dineika Raimundas Arnas Folded roof
CZ288032B6 (cs) * 1991-12-18 2001-04-11 Aktiebolaget Astra Farmaceutický prostředek pro podání inhalací
ES2107806T3 (es) * 1992-12-24 1997-12-01 Rhone Poulenc Rorer Ltd Nuevos esteroides.
BR9307746A (pt) * 1993-01-08 1995-11-14 Astra Ab Derivados de esteróides especificos para otratamento de cólon e ileo
GB9423919D0 (en) * 1994-11-26 1995-01-11 Rhone Poulenc Rorer Ltd Chemical process
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
DE29717252U1 (de) * 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
AU777770C (en) 1999-05-04 2005-11-10 Strakan International Limited Androgen glycosides and androgenic activity thereof
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009613D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
WO2004033478A2 (en) * 2002-10-08 2004-04-22 Sepracor Inc. Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
JP2006523674A (ja) * 2003-04-18 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 慢性閉塞性肺疾患(copd)のための組合せ治療法
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
AR045536A1 (es) * 2003-08-29 2005-11-02 Ranbaxy Lab Ltd Inhibidores de la fosfodiesterasa tipo -iv
EP1694655A2 (de) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesteraseinhibitoren
AU2005233569B2 (en) 2004-04-09 2010-08-19 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
EP1948167A1 (de) * 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Zusammensetzungen von phosphodiesterase-typ-iv-hemmern
WO2007056181A2 (en) * 2005-11-02 2007-05-18 Sicor, Inc. Process for the preparation of ciclesonide
AR059216A1 (es) 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
NZ574905A (en) 2006-08-22 2011-12-22 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
CA2664247A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
ES2529147T3 (es) 2006-12-26 2015-02-17 Pharmacyclics, Inc. Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación
PL2109608T3 (pl) 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
US10201490B2 (en) 2007-02-14 2019-02-12 Polichem Sa Use of chitosans for the treatment of nail inflammatory diseases
EP1958639A1 (de) 2007-02-14 2008-08-20 Polichem S.A. Verwendung von Chitosanen zur Behandlung von Entzündungserkrankungen der Nägel
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
MX2009009793A (es) * 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090082319A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched budesonide
WO2009045539A2 (en) 2007-10-05 2009-04-09 Nektar Therapeutics Al, Corporation Oligomer-corticosteroid conjugates
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (de) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. 4-(2-Amino-1-hydroxyethyl)Phenol-Derivate als Agonisten des b2-adrenergen Rezeptors
ES2401057T3 (es) * 2008-03-13 2013-04-16 Farmabios S.P.A. Procedimiento para la preparación de derivados de pregnano
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (de) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Zusammensetzungen von Phosphodiesterase-IV-Hemmern
CN101279997B (zh) * 2008-05-29 2011-08-24 鲁南制药集团股份有限公司 布地奈德的一种制备方法
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
EP2228368A1 (de) 2009-03-12 2010-09-15 Almirall, S.A. Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
RU2580315C3 (ru) 2009-05-29 2021-06-18 Перл Терапьютикс, Инк. Композиции для респираторной доставки активных веществ и связанные с ними способы и системы
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
UA108360C2 (uk) 2009-10-01 2015-04-27 Тверда фармацевтична композиція кортикостероїду, що розпадається у ротовій порожнині
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2011093812A2 (en) 2010-01-28 2011-08-04 Mahmut Bilgic Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
WO2011097594A2 (en) 2010-02-08 2011-08-11 Kinagen, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
CN101863952B (zh) * 2010-04-30 2013-04-17 湖北葛店人福药业有限责任公司 布地奈德的制备方法
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
SI2606134T1 (sl) 2010-08-17 2019-08-30 Sirna Therapeutics, Inc. RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (de) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Kondensierte pyrazolderivate als neue erk-hemmer
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
IN2013MN02170A (de) 2011-04-21 2015-06-12 Piramal Entpr Ltd
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
EP2578570A1 (de) 2011-10-07 2013-04-10 Almirall, S.A. Neues Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxychinolin-2(1H)-on mittels neuen Synthesezwischenstoffen
EP2770987B1 (de) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Neue verbindungen als erk-hemmer
WO2013109210A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising budesonide
EP2641900A1 (de) 2012-03-20 2013-09-25 Almirall, S.A. Neuartige polymorphe Kristallformen von 5-(2-{[6-(2,2-difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on, Heminapadisylat als Agonist des beta2-adrenergen Rezeptors
EP3919620A1 (de) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
CN103421075B (zh) * 2012-05-16 2017-07-28 上海特化医药科技有限公司 孕烷衍生物16,17‑缩醛(酮)的制备方法
WO2014007781A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US20150165037A1 (en) 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
JP6453218B2 (ja) 2012-08-24 2019-01-16 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 疾患を治療するためのhif活性の複素環式修飾物質
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Erk阻害剤である新規化合物
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
EP2999460A1 (de) 2013-05-22 2016-03-30 Pearl Therapeutics, Inc. Zusammensetzungen, verfahren und systeme für die respiratorische verabreichung von drei oder mehr wirkstoffen
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3250211B1 (de) 2015-01-30 2021-12-22 Coral Drugs Pvt. Ltd. Neuartiges verfahren zur herstellung von glucocorticoidsteroiden
EP3475275B1 (de) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 3-aryl- und heteroarylsubstituierte 5-trifluormethyloxadiazole als histondeacetylase 6 (hdac6)-inhibitoren
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US10711032B2 (en) 2016-11-08 2020-07-14 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
AU2018270784B2 (en) 2017-05-18 2024-05-16 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
SG11202006510XA (en) 2018-01-08 2020-08-28 Regeneron Pharma Steroids and antibody-conjugates thereof
KR20210008008A (ko) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 항-msr1 항체 및 이의 사용 방법
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
BR112022012032A2 (pt) 2019-12-17 2022-09-06 Merck Sharp & Dohme Llc Inibidores de prmt5
MX2024000468A (es) 2021-07-09 2024-04-05 Astrazeneca Pharmaceuticals Lp Composiciones, metodos y sistemas para la administracion de farmacos en aerosol.
CN118414148A (zh) 2021-12-20 2024-07-30 阿斯利康(瑞典)有限公司 用于气溶胶药物递送的组合物、方法和系统
US20240116945A1 (en) 2022-09-02 2024-04-11 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
WO2024091437A1 (en) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
WO2024129628A1 (en) 2022-12-14 2024-06-20 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) * 1964-03-24 Chioacyl
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US2990401A (en) * 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae
JPS4843910A (de) * 1971-10-08 1973-06-25

Also Published As

Publication number Publication date
YU35896B (en) 1981-08-31
NO139640B (no) 1979-01-08
US3929768A (en) 1975-12-30
FI50631B (de) 1976-02-02
BE799727A (fr) 1973-09-17
GB1429922A (en) 1976-03-31
YU129173A (en) 1981-02-28
AT328630B (de) 1976-03-25
CY1013A (en) 1979-11-23
ZA732955B (en) 1974-04-24
SU470954A3 (ru) 1975-05-15
PL87765B1 (de) 1976-07-31
JPS4941378A (de) 1974-04-18
NL177493B (nl) 1985-05-01
DE2323215B2 (de) 1977-08-11
NO139640C (no) 1979-04-18
DE2323215A1 (de) 1973-11-29
HU166680B (de) 1975-05-28
DD104295A5 (de) 1974-03-05
US3983233A (en) 1976-09-28
DE2323215C3 (de) 1978-03-30
IL42155A0 (en) 1973-07-30
CS178129B2 (de) 1977-08-31
CA1002938A (en) 1977-01-04
NL930025I1 (nl) 1993-06-01
FR2185405A1 (de) 1974-01-04
IL42155A (en) 1977-06-30
JPS5521760B2 (de) 1980-06-12
NL7306978A (de) 1973-11-21
DK134783B (da) 1977-01-17
ATA436573A (de) 1975-06-15
NO1994013I1 (no) 1994-08-31
AU5525373A (en) 1974-11-07
FR2185405B1 (de) 1976-12-31
CH595400A5 (de) 1978-02-15
KE2970A (en) 1979-07-20
SE378109B (de) 1975-08-18
DK134783C (de) 1977-06-06
HK49179A (en) 1979-07-27
ES414673A1 (es) 1976-07-01
FI50631C (fi) 1976-05-10

Similar Documents

Publication Publication Date Title
NL177493C (nl) Werkwijze voor de bereiding van steroiden en werkwijze ter bereiding van een farmaceutisch preparaat tegen ontstekingen.
NL7507798A (nl) Werkwijze voor de bereiding van een farmaceutisch preparaat.
NL7311307A (nl) Werkwijze voor de bereiding van een zoetstof.
NL7411312A (nl) Werkwijze voor de bereiding van een farmaceu- tisch preparaat.
NL7412108A (nl) Werkwijze voor de bereiding en toepassing van een hydrofiel harsmengsel.
NL7504216A (nl) Werkwijze voor de bereiding van een farmaceutisch preparaat.
NL153171B (nl) Werkwijze voor de bereiding van indanonderivaten en werkwijze voor de bereiding van een preparaat.
NL7513064A (nl) Werkwijze voor de bereiding van een farmaceutisch preparaat.
NL176945C (nl) Werkwijze voor het bereiden van ontstekingsremmende geneesmiddelen en daarvoor geschikte d-homosteroiden.
NL176458C (nl) Werkwijze ter bereiding van een farmaceutisch preparaat en werkwijze voor de bereiding van daartoe geschikte actieve stoffen.
NL7501680A (nl) Werkwijze voor de bereiding van een farmaceu- tisch preparaat.
NL7506872A (nl) Werkwijze voor de bereiding van een farmaceutische preparaat.
NL7511343A (nl) Werkwijze voor de bereiding van een farmaceutisch preparaat.
NL138919B (nl) Werkwijze voor de bereiding van een geneesmiddel en van een geneeskrachtige verbinding.
NL176228C (nl) Werkwijze voor de bereiding van een farmaceutisch preparaat met anti-inflammatoire werking, dat een jodofoor en een steroide bevat.
NL144923B (nl) Werkwijze voor de bereiding van een nalfa-gesubstitueerd 2-0-methyloxytocinederivaat, werkwijze ter bereiding van farmaceutische preparaten en gevormde preparaten.
NL173403C (nl) Werkwijze voor de bereiding van cumarine of een methylcumarine.
NL172549C (nl) Werkwijze voor de bereiding van deltaÿ4-3-oxo-1alfa-methylsteroiden en gevormd geneesmiddel dat een aldus verkregen steroide bevat.
NL152544B (nl) Werkwijze voor de bereiding van een 6-methyleentetracycline.
NL171860C (nl) Werkwijze voor de bereiding van een roentgencontrastmiddel.
NL177217C (nl) Werkwijze voor de bereiding van een geneesmiddel met steroide-hormooneigenschappen, gevormd geneesmiddel en werkwijze ter bereiding van daarvoor geschikte geneeskrachtige verbindingen.
NL7416236A (nl) Werkwijze voor de bereiding van een farmaceu- tisch preparaat en aldus verkregen gevormde preparaten.
NL162403B (nl) Werkwijze voor de bereiding van een trans-poly- -pentenameer.
NL161427C (nl) Werkwijze voor de bereiding van indaanderivaten en werkwijze voor de bereiding van een preparaat .
NL169323C (nl) Werkwijze ter bereiding van anti-inflammatoir werkzame farmaceutische preparaten en werkwijze ter bereiding van een anti-inflammatoir werkzaam pregnadienopyrazoolderivaat.

Legal Events

Date Code Title Description
BC A request for examination has been filed
CNR Transfer of rights (patent application after its laying open for public inspection)

Free format text: AKTIEBOLAGET DRACO

A85 Still pending on 85-01-01
AC1 Application for a supplementary protection certificate

Free format text: 930025, 930413

V4 Discontinued because of reaching the maximum lifetime of a patent
AC1 Application for a supplementary protection certificate

Free format text: 930025, 930413

BC1 Further communications concerning applications for a supplementary protection certificate

Free format text: 930025

AC1 Application for a supplementary protection certificate

Free format text: 930025, 930413

BC1 Further communications concerning applications for a supplementary protection certificate

Free format text: 930025